Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial

Keith S Kaye, Louis B Rice, Aaron L Dane, Viktor Stus, Olexiy Sagan, Elena Fedosiuk, Anita F Das, David Skarinsky, Paul B Eckburg, Evelyn J Ellis-Grosse, Keith S Kaye, Louis B Rice, Aaron L Dane, Viktor Stus, Olexiy Sagan, Elena Fedosiuk, Anita F Das, David Skarinsky, Paul B Eckburg, Evelyn J Ellis-Grosse

Abstract

Background: ZTI-01 (fosfomycin for injection) is an epoxide antibiotic with a differentiated mechanism of action (MOA) inhibiting an early step in bacterial cell wall synthesis. ZTI-01 has broad in vitro spectrum of activity, including multidrug-resistant Gram-negative pathogens, and is being developed for treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) in the United States.

Methods: Hospitalized adults with suspected or microbiologically confirmed cUTI/AP were randomized 1:1 to 6 g ZTI-01 q8h or 4.5 g intravenous (IV) piperacillin-tazobactam (PIP-TAZ) q8h for a fixed 7-day course (no oral switch); patients with concomitant bacteremia could receive up to 14 days.

Results: Of 465 randomized patients, 233 and 231 were treated with ZTI-01 and PIP-TAZ, respectively. In the microbiologic modified intent-to-treat (m-MITT) population, ZTI-01 met the primary objective of noninferiority compared with PIP-TAZ with overall success rates of 64.7% (119/184 patients) vs 54.5% (97/178 patients), respectively; treatment difference was 10.2% (95% confidence interval [CI]: -0.4, 20.8). Clinical cure rates at test of cure (TOC, day 19-21) were high and similar between treatments (90.8% [167/184] vs 91.6% [163/178], respectively). In post hoc analysis using unique pathogens typed by pulsed-field gel electrophoresis, overall success rates at TOC in m-MITT were 69.0% (127/184) for ZTI-01 versus 57.3% (102/178) for PIP-TAZ (difference 11.7% 95% CI: 1.3, 22.1). ZTI-01 was well tolerated. Most treatment-emergent adverse events, including hypokalemia and elevated serum aminotransferases, were mild and transient.

Conclusions: ZTI-01 was effective for treatment of cUTI including AP and offers a new IV therapeutic option with a differentiated MOA for patients with serious Gram-negative infections.

Clinical trial registration: NCT02753946.

Keywords: ZTI-01; acute pyelonephritis; complicated urinary tract infection; fosfomycin.

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Study design. N: Number of patients in the ITT population. Percentages were calculated using the number of patients in the ITT population as the denominator. A, Completed study drug was defined as completing 7 to 14 days of treatment. B, Only included patients who received study drug. Patient 1401–16 had an adverse event and did not receive study drug. Abbreviations: ITT, intent-to-treat; LFU, late follow-up; PIP-TAZ, piperacillin-tazobactam; TOC, test of cure; ZTI-01, fosfomycin for injection.
Figure 2.
Figure 2.
Analysis population disposition. Percentages were calculated using the number of patients in the ITT population as the denominator. Abbreviations: CE, clinical evaluable; CFU, colony-forming unit; EOT, end of treatment; I/E, inclusion/exclusion; ITT, intent-to-treat; LFU, late follow-up; ME, microbiologic evaluable; MITT, modified intent to treat; m-MITT, microbiologic modified intent to treat; PIP-TAZ, piperacillin-tazobactam; TOC, test of cure; ZTI-01, fosfomycin for injection.

References

    1. Alemayehu D, Quinn J, Cook J, Kunkel M, Knirsch CA. A paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens. Clin Infect Dis 2012; 55:562–7.
    1. Shields RK, Potoski BA, Haidar G, et al. . Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 2016; 63:1615–8.
    1. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev 2016; 29:321–47.
    1. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents 2010; 35:240–3.
    1. Monurol (fosfomycin tromethamine) sachet prescribing information, 2011 February. Available at: . Accessed 21 September 2017.
    1. Grabein B, Graninger W, Rodríguez Baño J, Dinh A, Liesenfeld DB. Intravenous fosfomycin-back to the future: systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect 2017; 23:363–72.
    1. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Available at: . Accessed 26 February 2019 2008.
    1. Piperacillin/Tazobactam 4g/0.5g powder for solution for infusion. Available at: . Accessed 24 October 2018.
    1. Eckburg PB, Skarinsky D, Das A, Ellis-Grosse EJ.. Phenotypic antibiotic resistance in ZEUS: multi-center, randomized, double-blind phase 2/3 study of ZTI-01 versus piperacillin-tazobactam (P-T) in the treatment of patients with complicated urinary tract infections (cUTI) including acute pyelonephritis (AP). ID Week. San Diego, California, 7 October 2017. Poster 1830.
    1. Wagenlehner FM, Sobel JD, Newell P, et al. . Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 2016; 63:754–62.
    1. Kaye KS, Bhowmick T, Metallidis S, et al. . Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA 2018; 319:788–99.
    1. Mocarski M, Zhao Q, Ding M, Dixit S, Lodise T. 1041Economic burden associated with key Gram-negative pathogens among patients with complicated urinary tract infections across US hospitals. Open Forum Infect Dis 2014; 1(Suppl 1):S305.
    1. Castañeda-García A, Blázquez J, Rodríguez-Rojas A. Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance. Antibiotics (Basel) 2013; 2:217–36.
    1. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 2012; 67:255–68.
    1. Pourbaix A, Guérin F, Lastours V, et al. . Biological cost of fosfomycin resistance in Escherichia coli in a murine model of urinary tract infection. Int J Med Microbiol 2017; 307:452–9.
    1. Iarikov D, Wassel R, Farley J, Nambiar S. Adverse events associated with fosfomycin use: review of the literature and analyses of the FDA adverse event reporting system database. Infect Dis Ther 2015; 4:433–58.
    1. Florent A, Chichmanian RM, Cua E, Pulcini C. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents 2011; 37:82–3.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner